Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial.

Tuckwell, Katie; Collinson, Neil; Dimonaco, Sophie; Klearman, Micki; Blockmans, Daniel; Brouwer, Elisabeth; Cid, Maria C.; Dasgupta, Bhaskar; Rech, Juergen; Salvarani, Carlo; Unizony, Sebastian H.; Stone, John H.

doi:10.1016/j.semarthrit.2016.11.002

Record: found
Abstract: found
Article: not found

Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial.

Author(s): Katie Tuckwell ¹ , Neil Collinson ¹ , Sophie Dimonaco ¹ , Micki Klearman ² , Daniel Blockmans ³ , Elisabeth Brouwer ⁴ , Maria C Cid ⁵ , Bhaskar Dasgupta ⁶ , Juergen Rech ⁷ , Carlo Salvarani ⁸ , Sebastian H Unizony ⁹ , John H Stone ¹⁰

Publication date (Electronic): Nov 15 2016

Journal: Seminars in arthritis and rheumatism

Publisher: Elsevier BV

Keywords: Biologicals, Clinical trial, Giant cell arteritis, Glucocorticoids, Positron emission tomography (PET)

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To report entry criteria and clinical features of patients with newly diagnosed and relapsing giant cell arteritis (GCA) enrolled in a randomized trial of tocilizumab, an interleukin-6 receptor-alpha inhibitor.